Ofev and Presyncope - a phase IV clinical study of FDA data

Summary:

Presyncope is reported as a side effect among people who take Ofev (nintedanib esylate), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Tyvaso, and have Idiopathic pulmonary fibrosis.

The phase IV clinical study analyzes which people have Presyncope when taking Ofev. It is created by eHealthMe based on reports of 24,754 people who have side effects when taking Ofev from the FDA, and is updated regularly.

What is Ofev?

Ofev has active ingredients of nintedanib esylate. eHealthMe is studying from 24,791 Ofev users. Check the latest studies of Ofev.

What is Presyncope?

Presyncope is found to be associated with 1,369 drugs and 1,286 conditions by eHealthMe. Check the latest studies of Presyncope.

On Jun, 18, 2026

24,754 people reported to have side effects when taking Ofev.
Among them, 41 people (0.17%) have Presyncope.

Among these 41 people:

How long have people been on Ofev when they have Presyncope? *

What is the gender of people who have Presyncope when taking Ofev? *

female: 65.85 %
male: 34.15 %

What is the age of people who have Presyncope when taking Ofev? *

What are other drugs people take besides Ofev? *

What are other side effects people have besides Presyncope? *

Diarrhea: 23 people, 56.10%
Dizziness: 14 people, 34.15%
Nausea And Vomiting: 12 people, 29.27%
Nausea (feeling of having an urge to vomit): 11 people, 26.83%
Fatigue (feeling of tiredness): 11 people, 26.83%
Dyspnea (difficult or laboured breathing): 10 people, 24.39%
Weight Decreased: 9 people, 21.95%
Weakness: 9 people, 21.95%
Chest Pain: 8 people, 19.51%
Abdominal Pain Upper: 7 people, 17.07%

What are the existing conditions these people have? *

Idiopathic Pulmonary Fibrosis (chronic lung disease): 23 people, 56.10%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 14 people, 34.15%
Interstitial Lung Disease: 7 people, 17.07%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 3 people, 7.32%
Systemic Sclerosis Pulmonary (an autoimmune or connective tissue disease. it is characterized by thickening of the skin with involvement of lungs): 2 people, 4.88%
Peripheral Swelling: 2 people, 4.88%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 2.44%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 2.44%
Pain: 1 person, 2.44%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 2.44%

* Approximation only. Some reports may have incomplete information.

Do you take Ofev and have Presyncope?

- Check whether Presyncope is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ofev:

Ofev (24,791 reports)

Presyncope treatments and more:

Presyncope (26,156 reports)

Browse all side effects of Ofev:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Presyncope:

Presyncope (1,369 drugs)

Browse all the conditions that are associated with Presyncope:

Presyncope (1,286 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nintedanib esylate (the active ingredients of Ofev) and Ofev (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.